Chargement en cours...
Update on reslizumab for eosinophilic asthma
INTRODUCTION: Patients with severe eosinophilic asthma have an unmet need for novel and efficacious treatments. Reslizumab is one of three monoclonal antibodies targeting the interleukin-5 (IL5) pathway and has been found in phase 3b clinical trials to reduce asthma exacerbations, control asthma-rel...
Enregistré dans:
| Publié dans: | Expert Opin Biol Ther |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5161345/ https://ncbi.nlm.nih.gov/pubmed/26372797 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14712598.2015.1090972 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|